Furlong Tammy 4
4 · Elevation Oncology, Inc. · Filed Feb 19, 2025
Insider Transaction Report
Form 4
Furlong Tammy
CHIEF FINANCIAL OFFICER
Transactions
- Exercise/Conversion
Restricted Stock Unit
2025-02-15−300→ 2,400 total→ Common Stock (300 underlying) - Exercise/Conversion
Common Stock
2025-02-15+9,375→ 10,785 total - Tax Payment
Common Stock
2025-02-15$0.67/sh−2,780$1,867→ 8,005 total - Exercise/Conversion
Common Stock
2025-02-15+300→ 8,305 total - Tax Payment
Common Stock
2025-02-15$0.67/sh−89$60→ 8,216 total - Award
Stock Option (Right to Buy)
2025-02-15+275,000→ 275,000 totalExercise: $0.67Exp: 2035-02-14→ Common Stock (275,000 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-02-15−9,375→ 28,125 total→ Common Stock (9,375 underlying)
Footnotes (5)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The stock option vests as to 25% of the total shares on February 15, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- [F3]25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- [F4]The RSUs do not expire; they either vest or are canceled prior to the vesting date.
- [F5]25% of the RSUs vested on February 15, 2024, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.